Back to Search
Start Over
Efficacy of B Cell Depletion Therapy with Rituximab in Refractory Chronic Recurrent Uveitis Associated with Vogt-Koyanagi-Harada Disease.
- Source :
-
Ocular immunology and inflammation [Ocul Immunol Inflamm] 2022 Apr 03; Vol. 30 (3), pp. 750-757. Date of Electronic Publication: 2020 Sep 29. - Publication Year :
- 2022
-
Abstract
- Purpose: To evaluate the efficacy of B cell depletion therapy with the chimeric mouse/human anti-CD20 monoclonal antibody rituximab for refractory chronic recurrent granulomatous uveitis associated with Vogt-Koyanagi-Harada (VKH) disease.<br />Methods: Retrospective study of 9 patients (18 eyes) who failed to respond to conventional combination immunosuppressive therapy.<br />Results: All the patients received 3 rituximab infusions. The follow-up period after initiation of rituximab therapy ranged from 9 to 36 months (mean ±SD, 19.2 ± 10.1). All patients achieved remission and visual acuity significantly improved ( p < .001). Rituximab provided corticosteroid-sparing effect along with control of inflammation. No rituximab-related complications were observed.<br />Conclusions: Rituximab is effective for the treatment of refractory chronic recurrent granulomatous uveitis associated with VKH disease.
Details
- Language :
- English
- ISSN :
- 1744-5078
- Volume :
- 30
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Ocular immunology and inflammation
- Publication Type :
- Academic Journal
- Accession number :
- 32990482
- Full Text :
- https://doi.org/10.1080/09273948.2020.1820531